Professor Moshe Inbar

• Breast cancer;
• Stomach cancer;
• Rectal cancer;
• Esophageal cancer;
• Prostate cancer;
• Ovarian cancer.

In some of his scientific papers, the professor explores the combined use of the biological drug bevacizumab and chemotherapy drugs in HER2-negative, locally advanced or metastatic breast cancer.

The problem of early breast cancer diagnosis is addressed in his work “PET in Women with High Risk for Breast or Ovarian Cancer” co-authored with Professor Einat Even-Sapir, leading Israeli specialist in nuclear medicine.

The professor emphasizes the importance of preserving high quality of life for cancer patients. In the article “Sexy Cancer – Sexuality for Cancer Patients” he presents physicians with a range of problems essential for cancer patients and their partners from diagnosis into all stages of treatment.

Professor Inbar’s research interests also include stage 4 ovarian cancer therapy. This topic is addressed in the study “Combined Weekly Carboplatin and Paclitaxel as Primary Treatment of Advanced Epithelial Ovarian Carcinoma”.

A separate study is devoted to the results of organ-preserving surgery for breast cancer with subsequent radiation therapy and treatment with hormone therapy drug tamoxifen.

Professor Inbar participates in the study of brachytherapy for prostate cancer. The results of this study were published in the article “Brachytherapy Combined with External Beam Radiation in Localized Prostate Cancer”.

Up until recently, Professor Inbar was Head of the Israeli Central Committee for Certification of Cancer Specialists. He was also in charge of the Israeli Breast Cancer Group (IBCG) and Israel Cancer Association (ICA).